Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 3/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28009406 | 1.00 | BRD4 (0.46) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1026647 | 1.00 | BRD4 (0.46) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Acetic Acid Methyl Ester SCHEMBL9151328 | 0.94 | BRD4 (0.42) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Propene SCHEMBL7744011 | 0.91 | BRD4 (0.40) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Dodecanol SCHEMBL28693387 | 0.83 | SLC5A1 (0.41) | BRD4KMT2APDE4APDE4BPDE4C | |
| SCHEMBL16612384 | 0.81 | BRD4 (0.43) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2153275 | 0.81 | BRD4 (0.43) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL8262495 | 0.81 | CHRNB2 (0.43) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL28009383 | 0.81 | MAPK1 (0.39) | ACACBSCN8A | |
| SCHEMBL14058597 | 0.79 | ALDH1A1 (0.41) | KMT2AACACBPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200239446-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239446-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G4A, PLA2G4C | BRD4 2552/4885CHRNB2 4348/4885CHRNA4 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.